Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Collaborators: German Hodgkin's Lymphoma Study Group; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Treatments: BB 1101; Bortezomib; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate

Criteria

Inclusion Criteria:

• Hodgkin's lymphoma

• Second or higher relapse (first relapse if high-dose chemotherapy not possible)

• Age >/= 18 years

• No major organ dysfunction or intercurrent disorder

• Written informed consent

Exclusion Criteria:

• Pregnant or nursing